Lisocabtagene maraleucel

Breyanzi · CAR-T · CD19

Mechanism

Anti-CD19 CAR T-cell therapy with defined CD4+/CD8+ T cell composition for more consistent dosing.

Indication in MCL

Under investigation for MCL

Approval Status

FDAUnder investigation for MCLApproved for DLBCL/FL; MCL trials ongoing

Key Trials

TRANSCEND-NHL-001

Key Researchers

Manali Kamdar

Associate Professor, Clinical Director of Lymphoma Services · University of Colorado

Related Papers (3)

Navigating the risks and benefits of newly approved Lisocabtagene Maraleucel in mantle cell lymphoma treatment.

Annals of medicine and surgery (2012) · Jun 2025

Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing/advanced practice provider perspectives.

Seminars in oncology nursing · Feb 2025

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Apr 2024